Singapore
Mirxes is a biotechnology company prioritizing the innovation of early, actionable, and personalized diagnoses to improve and save lives, particularly through cancer detection. Headquartered in Singapore, Mirxes is building a robust product lineup, most notably with GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, boasting a detection rate of 90% for Stage I and II cancers.
Founded in 2014, Mirxes originated from the A*STAR Bioprocessing Technology Institute, demonstrating a strong commitment to leveraging cutting-edge, qPCR-based technology for microRNA detection. Their comprehensive strategy targets cancer detection first, with imminent tests for lung, thyroid, colorectal, breast, liver, and ovarian cancers over the next several years. The company is also advancing its offerings in precision oncology and expanding to address other critical health areas like cardiovascular, metabolic, and infectious diseases.
Globally, Mirxes has established research and clinical operations in USA, Japan, and China, with a wide-reaching sales and distribution network. Their strategic, Asia-centered growth, paired with a solid technological pedigree, positions them as a promising contender in the biotech industry.
